The JAK2-Akt-glycogen synthase kinase-3β signaling pathway is involved in toll-like receptor 2-induced monocyte chemoattractant protein-1 regulation

Molecular Medicine Reports

Volumn 5, Issue 4, 2012, Pages 1063-1067

  Park, Dae Weon ^a   Lee, Hyung Kyoung ^a   Jeong, Tae Whal ^b   Kim, Jin Sik ^a   Bae, Yoe Sik ^c   Chin, Byung Rho ^b   Baek, Suk Hwan ^a  

^a Yeungnam University   (South Korea)

^b Yeungnam University College of Medicine   (South Korea)

^c Sungkyunkwan University   (South Korea)

Author keywords

Akt; Glycogen synthase kinase 3 ; Janus kinase 2; Monocyte chemoattractant protein 1; Toll like receptor

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; GLYCOGEN SYNTHASE KINASE 3BETA; JANUS KINASE 2; LITHIUM CHLORIDE; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; MYELOID DIFFERENTIATION FACTOR 88; PROTEIN KINASE B; PROTEIN KINASE B INHIBITOR; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR AGONIST; TOLL LIKE RECEPTOR AGONIST PAM3CSK4; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BONE MARROW; CONTROLLED STUDY; DOWNSTREAM PROCESSING; ENZYME INACTIVATION; ENZYME PHOSPHORYLATION; MACROPHAGE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; REGULATORY MECHANISM; WESTERN BLOTTING;

ANIMALS; CELL LINE, TUMOR; CHEMOKINE CCL2; CHROMONES; GLYCOGEN SYNTHASE KINASE 3; JANUS KINASE 2; LIPOPEPTIDES; LITHIUM CHLORIDE; MICE; MICE, KNOCKOUT; MORPHOLINES; MYELOID DIFFERENTIATION FACTOR 88; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTOR 2;

MUS;

EID: 84863231838     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2012.741     Document Type: Article

References (32)

1. Mencin A, Kluwe J and Schwabe RF: Toll-like receptors as targets in chronic liver diseases. Gut 58: 704-720, 2009.
2. Akira S: Toll-like receptor signaling. J Biol Chem 278: 38105-38108, 2003.
3. Frantz S, Ertl G and Bauersachs J: Mechanisms of disease: Toll-like receptors in cardiovascular disease. Nat Clin Pract Cardiovasc Med 4: 444-454, 2007. (Pubitemid 47180328)
4. Akira S, Uematsu S and Takeuchi O: Pathogen recognition and innate immunity. Cell 124: 783-801, 2006. (Pubitemid 43261452)
5. Kang JY, Nan X, Jin MS, et al: Recognition of lipopeptide patterns by Toll-like receptor 2-Toll-like receptor 6 heterodimer. Immunity 31: 873-884, 2009.
6. Schoneveld AH, Hoefer I, Sluijter JP, Laman JD, de Kleijn DP and Pasterkamp G: Atherosclerotic lesion development and Toll like receptor 2 and 4 responsiveness. Atherosclerosis 197: 95-104, 2008. (Pubitemid 351273277)
7. Liu X, Ukai T, Yumoto H, et al: Toll-like receptor 2 plays a critical role in the progression of atherosclerosis that is independent of dietary lipids. Atherosclerosis 196: 146-154, 2008.
8. Mullick AE, Tobias PS and Curtiss LK: Modulation of atherosclerosis in mice by Toll-like receptor 2. J Clin Invest 115: 3149-3156, 2005. (Pubitemid 41567579)
9. Kuwahata S, Fujita S, Orihara K, et al: High expression level of Toll-like receptor 2 on monocytes is an important risk factor for arteriosclerotic disease. Atherosclerosis 209: 248-254, 2010.
10. Monaco C, Terrando N and Midwood KS: Toll-like receptor signaling: common pathways that drive cardiovascular disease and rheumatoid arthritis. Arthritis Care Res (Hoboken) 63: 500-511, 2011.
11. Mullick AE, Soldau K, Kiosses WB, Bell TA III, Tobias PS and Curtiss LK: Increased endothelial expression of Toll-like receptor 2 at sites of disturbed blood flow exacerbates early atherogenic events. J Exp Med 205: 373-383, 2008. (Pubitemid 351281603)
12. Abe Y, Kawakami A, Osaka M, et al: Apolipoprotein CIII induces monocyte chemoattractant protein-1 and interleukin 6 expression via Toll-like receptor 2 pathway in mouse adipocytes. Arterioscler Thromb Vasc Biol 30: 2242-2248, 2010.
13. Cao F, Castrillo A, Tontonoz P, Re F and Byrne GI: Chlamydia pneumoniae-induced macrophage foam cell formation is mediated by Toll-like receptor 2. Infect Immun 75: 753-759, 2007. (Pubitemid 46203437)
14. Zernecke A, Shagdarsuren E and Weber C: Chemokines in atherosclerosis: an update. Arterioscler Thromb Vasc Biol 28: 1897-1908, 2008.
15. Koenen RR and Weber C: Therapeutic targeting of chemokine interactions in atherosclerosis. Nat Rev Drug Discov 9: 141-153, 2010.
16. Ni CW, Wang DL, Lien SC, Cheng JJ, Chao YJ and Hsieh HJ: Activation of PKC-epsilon and ERK1/2 participates in shear-induced endothelial MCP-1 expression that is repressed by nitric oxide. J Cell Physiol 195: 428-434, 2003. (Pubitemid 36529870)
17. Arndt PG, Suzuki N, Avdi NJ, Malcolm KC and Worthen GS: Lipopolysaccharide-induced c-Jun NH2-terminal kinase activation in human neutrophils: role of phosphatidylinositol 3-Kinase and Syk-mediated pathways. J Biol Chem 279: 10883-10891, 2004. (Pubitemid 38401578)
18. Park DW, Baek K, Kim JR, et al: Resveratrol inhibits foam cell formation via NADPH oxidase 1-mediated reactive oxygen species and monocyte chemotactic protein-1. Exp Mol Med 41: 171-179, 2009.
19. Tsai CS, Lin FY, Chen YH, et al: Cilostazol attenuates MCP-1 and MMP-9 expression in vivo in LPS-administrated balloon-injured rabbit aorta and in vitro in LPS-treated monocytic THP-1 cells. J Cell Biochem 103: 54-66, 2008.
20. Lee JG, Lee SH, Park DW, et al: Toll-like receptor 9-stimulated monocyte chemoattractant protein-1 is mediated via JNK-cytosolic phospholipase A2-ROS signaling. Cell Signal 20: 105-111, 2008.
21. Braunersreuther V, Mach F and Steffens S: The specific role of chemokines in atherosclerosis. Thromb Haemost 97: 714-721, 2007. (Pubitemid 46804314)
22. Ahmad R, El Bassam S, Cordeiro P and Menezes J: Requirement of TLR2-mediated signaling for the induction of IL-15 gene expression in human monocytic cells by HSV-1. Blood 112: 2360-2368, 2008.
23. Park JE, Kim YI and Yi AK: Protein kinase D1 is essential for MyD88-dependent TLR signaling pathway. J Immunol 182: 6316-6327, 2009.
24. Chen S, Sorrentino R, Shimada K, et al: Chlamydia pneumoniae-induced foam cell formation requires MyD88-dependent and -independent signaling and is reciprocally modulated by liver X receptor activation. J Immunol 181: 7186-7193, 2008.
25. Okugawa S, Ota Y, Kitazawa T, et al: Janus kinase 2 is involved in lipopolysaccharide-induced activation of macrophages. Am J Physiol Cell Physiol 285: C399-C408, 2003. (Pubitemid 36917855)
26. Kamezaki K, Shimoda K, Numata A, Matsuda T, Nakayama K and Harada M: The role of Tyk2, Stat1 and Stat4 in LPS-induced endotoxin signals. Int Immunol 16: 1173-1179, 2004. (Pubitemid 39136734)
27. Rebouissou S, Amessou M, Couchy G, et al: Frequent in-frame somatic deletions activate gp130 in inflammatory hepatocellular tumours. Nature 457: 200-204, 2009.
28. Rosell R, Bertran-Alamillo J, Molina MA and Taron M: IL-6/gp130/STAT3 signaling axis in cancer and the presence of in-frame gp130 somatic deletions in inflammatory hepatocellular tumors. Future Oncol 5: 305-308, 2009.
29. Lee IT, Lee CW, Tung WH, et al: Cooperation of TLR2 with MyD88, PI3K, and Rac1 in lipoteichoic acid-induced cPLA2/COX-2-dependent airway inflammatory responses. Am J Pathol 176: 1671-1684, 2010.
30. Brown GT and McIntyre TM: Lipopolysaccharide signaling without a nucleus: kinase cascades stimulate platelet shedding of proinflammatory IL-1beta-rich microparticles. J Immunol 186: 5489-5496, 2011.
31. Hirata N, Yanagawa Y, Iwabuchi K and Onoe K: Selective regulation of interleukin-10 production via Janus kinase pathway in murine conventional dendritic cells. Cell Immunol 258: 9-17, 2009.
32. Martin M, Rehani K, Jope RS and Michalek SM: Toll-like receptor-mediated cytokine production is differentially regulated by glycogen synthase kinase 3. Nat Immunol 6: 777-784, 2005. (Pubitemid 43090463)